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Preface 
Animal models are extensively used to understand how cancer develops and spreads throughout 
the body and to test the efficacy of new therapeutic drugs (Céspedes et al., 2006; Morton and 
Houghton, 2007; Workman et al., 2010). Preclinical cancer studies carried out on animal models 
fall into two broad categories: 
- those using tumor cell transplantation; 
- those in which tumors arise or are induced in the host. 
 
Transplantation tumor models involve the transplantation of mouse or rat tumor cells into a host 
of the same species and strain (syngeneic or allograft) or the growth of human tumor cells into 
mice (xenograft) that are immunodeficient to prevent rejection. Syngeneic models have the 
advantage to use conventional rodents and normal housing conditions and mimic immune and 
stromal interactions, but are not applicable if investigating human-specific parameters. On the 
other hand, xenograft models do not allow the study of the interaction with the host immune system 
and have in general limited metastastic potential. The simplest approach to engraft transplantable 
tumors is subcutaneously (s.c.). This technique is easily performed and allows a daily monitoring of 
tumor growth, but it should be considered that the subcutis is an ectopic site for most tumors and 
metastases rarely develop from subcutaneously implanted tumors. Orthotopic transplantation of 
human tumor xenografts in immunosuppressed mice implies grafting a tissue in its natural location 
thus better reproducing the clinical behavior of the tumor (Céspedeset al., 2006; Richmond and Su, 
2008), but on the other hand is a time consuming, expensive and technically challenging approach 
(Richmond and Su, 2008). Furthermore, an additional engrafting method relies on the implant of 
tumor cells within the peritoneal cavity (i.p.), thus maximizing the chance of transcoelomatic 
spread. 
 
The successful engraftment of human tumors largely relies on the immunodeficient state of mice. 
Briefly, there are several degrees of immunocompromission in mice, listed below in a progressively 
severe grade of immunodeficiency: 
- nude mice are athymic homozygotes for the nude spontaneous mutation (Foxn1nu/nu) and lack 
T cells and are thus incapable of cell-mediated immunity, with a partially defective B cell 
development. Furthermore, they have an abnormal hair growth, so that subcutaneously 
transplanted tumors are easily visible and measurable; 
- Rag1 mice are homozygotes for Rag1tm1Mom knockout mutation and do not produce mature T or 
B cells, thus being more immunocompromised than nude ones. However, they do have an 
intact innate immunity; 
- non-obese diabetic or NOD mice are homozygous for the severe combined immune 
deficiency spontaneous mutation (Prkdcscid or scid) and have severely compromised innate and 
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adaptive immunity, lacking both B and T lymphocytes, reduced NK cell activity and impaired 
complement pathway (Kavirayani and Foreman, 2010);  
- NOD.Cg-Rag1tm1MomPrf1tm1Sdz are double homozygous knockout on the NOD background, with 
no mature T or B cells, no detectable NK cell cytotoxic activity and no serum immunoglobulin; 
- NOD.Cg-Prkdcscid B2mtm1Uncare double homozygous knockout on the NOD background. These 
mice are MHC I-deficient, B and T cell-deficient, complement deficient and have few NK cells; 
- NOD.Cg-PrkdcscidIl2rgtm1Wjl, also known as NOD scid gamma (NSG), lack mature T, B, 
functional NK cells, hemolytic complement and are deficient in signaling in multiple cytokines, 
such as IL2, IL4, IL7, IL9, IL15 and IL21 (Foreman et al., 2011); 
- NOD.Cg-Rag1tm1MomIl2tm1Wjl, also known as NOD-Rag1 gamma (NRG), are as severely 
immunocompromised as NSG, but tolerate much higher levels of irradiation. 
 
The predictive value of these models has been extensively debated. The usefulness of these in 
vivo models of cancer will depend on how close they replicate the human disease. The major 
advantages of xenografts models are that they recapitulate growth, histopathological features and 
biological behavior of the original cancers, such as protein expression, tumor biomarker status and 
genomic and genetic status. On the other hand, they lack tumor original microenvironment, 
especially tumor-associated stroma, the host immune system is lost because of 
immunocompromission induced in mice and the full manifestation of metastatic potential is 
generally hampered (Jin et al., 2010). 
 
Autochthonous tumor models include two broad categories: those spontaneously arising in 
outbred or inbred rodents or induced by chemical carcinogens, radiation, viruses or bacteria and/or 
those from genetically engineered mice (GEM), whose genetic profile is altered such that one or 
more genes thought to be involved in transformation or malignancy are mutated, deleted or 
overexpressed. 
 
During the course of my PhD, I dealt with a wide array of different experimental studies based on 
xenografting of primary human tumor tissue in immunodeficient mice. The aim of this thesis is to 
provide a basic panel for a pathological approach to human xenografts, with detailed references to 
subcutaneous (s.c.) xenograft models and intraperitoneal (i.p.) xenograft models and to promising 
metastatic models. The goals of my three-year-research are to discuss how each model has been 
utilized to provide insights into human cancer therapy and to provide an assessment of the 
strengths and limitations of each model. 
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Chapter 1- Subcutaneous xenografts 
Subcutaneous xenografts are generally implanted within the subcutis of the flank. Implantation of 
tumor material is performed using a trochar or surgical formation of a small subcutaneous pocket 
(Workman et al., 2010). Appropriate anaesthetics must be used and post-implantation analgesia is 
also strongly recommended. This technique implies advantages such a minimal technical effort to 
perform the engraftment and tumor growth can be monitored extremely easily through daily caliper 
measurements. 
 
1.1 - Sampling 
To maximize histopathological studies, subcutaneous xenografts should be collected with broad 
borders, involving skin and with fascial/subcutaneous tissues, as depicted in Figure 1. 
 
 Fig. 1. Correct sampling technique of a subcutaneous xenograft. 
 
This approach would allow a proper orientation of the sample, keeping topographic relations 
between human neoplastic cells and surrounding murine tissues, and would allow to evaluate 
xenograft-surrounding microenvironment cross-talk, with peculiar emphasis on capsular reaction, 
infiltrative vs expansile growth and peritumoral vessel embolization. Furthermore, adjacent normal 
tissues could be used as inner positive and/or negative controls for further immunohistochemical 
(IHC) trials. 
 
Further details regarding sampling procedures are provided in Figures 2 to 4. 
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Fig. 2. To optimize the procedure, the xenograft can be placed on dry 
tissue paper after sampling and put in formalin. 
  
  
Fig. 3. After an optimal 48-hour-fixation period in 10% buffered 
formalin the sample can be trimmed. 
  
  
 
Fig. 4. Trimmed samples are then put in a biocassette, ready for paraffin 
embedding. 
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1.2- General evaluation 
For histopathological examination 4 µm sections from each tumor xenograft are routinely stained 
with Hematoxylin and Eosin (HE) and evaluated under a light microscope. Briefly, a general 
description of the tumor xenograft according to the Armed Forces Institute of Pathology (AFIP) 
guidelines is provided and specific parameters summarized in Table 1 are evaluated for each 
xenograft. 
 
Tab. 1. Histopathological parameters evaluated for the analysis of subcutaneous xenografts. 
Evaluated 
parameter Description 
Prevalent pattern 
of growth  Solid areas; lobules; tubules; acini; bundles; packets; etc.  
Necrosis  
0 = no intratumoral necrotic foci;  
1 = necrotic foci accounting for less than 20% of tumor extension;  
2 = necrotic foci comprised between 20% and 50% of tumor extension;  
3 = necrotic foci comprised between 50% and 70% of tumor extension;  
4 = necrotic foci accounting for more than 70% of tumor extension.  
Stroma 
0 = no stroma;  
1 = scant amount of stroma mainly characterized by delicate fibrovascular septa 
separating groups of neoplastic cells;  
2 = moderate amount of stroma characterized by a combination of delicate 
fibrovascular septa and broad bundles of fibrous connective tissue separating and 
embedding groups of neoplastic cells;  
3 = abundant stroma mainly composed of broad bundles of fibrous connective tissue 
separating and embedding groups of neoplastic cells.  
Peripheral 
invasion  
0= absent  
1= focal  
2= multifocal  
3= diffuse 
Capsule 0= absent 1= present 
Mitoses Number of mitoses in 3 randomly selected high power fields (HPF=400x) 
Apoptoses Number of apoptotic cells in the same 3 high power fields evaluated for mitotic index (HPF=400x) 
 
This evaluation is generally performed in a blind fashion and data are associated with different 
study groups only afterwards. 
 
An example of this approach is reported below. 
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Experiment I - General approach to a subcutaneous xenograft 
In collaboration with IRCCS, Istituto Nazionale dei Tumori of Milan the effects of several preclinical 
antitumor agents were tested on pediatric sarcoma xenografts. 
 
The aim of this study was to evaluate the effects of compound exhibiting a pleiotropic activity on 
proliferative/survival pathways on tumor mitotic/apoptotic rate in a pediatric rhabdomyosarcoma 
cell line. 
 
Material and Methods 
Nude CD1 Swiss female mice were injected subcutaneously with human rhabdomyosarcoma cells 
(RD) and divided into 2 groups: 
-control (CRL, mice 1, 5, 9, SS); 
-mice treated with the tested compoud (Cpt 1, mice 1, 2, 5, 7). 
 
Excised tumor xenografts and adjacent tissues were routinely formalin fixed and paraffin 
embedded. Four µm sections from each tumor xenograft were routinely stained with Hematoxylin-
Eosin (HE) and evaluated under a light microscope for histopathological examination. A description 
of the general phenotype of tumors was made and histological evaluation of main morphological 
features previously outlined has been performed according to the criteria proposed in Table 1. 
 
Results 
In general, the following morphological features were observed in all examined samples: densely 
cellular, well demarcated, partially encapsulated nodular mass, expanding subcutis and 
occasionally the mammary fat pad. The mass was composed of solid areas, with scant to 
moderate fibrovascular stroma. Neoplastic cells were polygonal to spindled, ranging from 20 to 40 
µm in diameter, with variably indistinct cell borders, an intermediate nuclear to cytoplasmic (N/C) 
ratio and a moderate amount of pale eosinophilic homogeneous cytoplasm. Nuclei were polygonal, 
15 µm in diameter, central, with vesicular chromatin and occasional 1-2 central prominent magenta 
nucleoli. High mitotic activity, often with atypical mitotic figures, mild anisocytosis and 
anisokaryosis, large numbers of apoptotic cells and intratumoral necrotic and hemorrhagic foci, 
occasionally with dystrophic mineralization were present. Exemplificative pictures are provided in 
Figures 5 and 6. 
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Fig.5. Subcutaneous undifferentiated, well demarcated solid xenograft 
with intratumoral broad areas of necrosis and hemorrhages. HE, 25x. 
  
  
 
Fig.6. Close up of Fig.5. Note bundles of fibrous connective tissue 
separating solid areas of neoplastic cells. HE, 100x. 
 
The histological evaluation of the main morphological features of examined xenografts is reported 
in Table 2 and summarized in Table 3. 
 
Tab.2. Histopathological parameters from experiment I. 
Sample 
Prevalent 
pattern of 
growth 
Necrosis Stroma Peripheral invasion 
Mitoses Apoptoses 
in 3 HPF Mean Tot. in 3 HPF Mean Tot. 
1 CTR solid 3 1 0 7; 4; 5 5,3 16 3; 2; 3 2,7 8 
5 CTR solid 3 2 0 8; 16; 7 10,3 31 1; 1; 4 2 6 
9 CTR solid 3 1 0 7; 4; 7 6 18 1; 6; 2 3 9 
SS CTR solid 3 1 0 11; 15; 6 10,7 32 3; 2; 1 2 6 
Mean 
 
3 1,2 0 
 
8,1 24,2 
 
2,4 7,2 
1 Cpt1 solid 3 1 0 2; 3; 9 4,7 14 9; 4; 2 5 15 
2 Cpt1 solid 2 1 0 6; 5; 5 5,3 16 1; 2; 2 1,7 5 
5 Cpt1 solid 4 2 0 0; 0; 0 0 0 4; 8; 10 7,3 22 
7 Cpt1 solid 1 1 0 8; 7; 4 6,3 19 7; 6; 2 5 15 
Mean 
 
2,5 1,2 0 
 
4,1 12,2 
 
4,7 14,2 
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Tab.3. Summary of the mean scores of histological results and of the mean numbers of mitoses and 
apoptosis reported in Tab.2. 
Group Necrosis Stroma Mitoses Apoptoses Mean Tot Mean Tot 
CTR 3 1,2 8,1 24,2 2,4 7,2 
Cpt1 2,5 1,2 4,1 12,2 4,7 14,2 
 
Comments 
Overall, tumor xenografts from experiment I had a similar pattern of growth (solid) and a similar 
behavior, with no peripheral invasion observed. Tumors were well demarcated, nodular and 
partially encapsulated. 
 
A trend towards decreased intratumoral necrosis and decreased mitotic index, with increased 
apoptotic index was observed in treated group compared to control one. 
 
In conclusion, an interference on tumoral proliferative/survival pathways elicited by the tested 
compound was confirmed by this pivotal study. 
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1.3- Evaluation of specific parameters and treatment-associated changes 
During the 3-year-period of my PhD, I evaluated changes in tumor growth and morphology 
associated with different therapeutic treatments. Parameters modulated by pharmacological trials 
mainly addressed tumor vasculature (angiogenesis) and the number and type of intratumoral 
mitoses and apoptosis. 
 
1.3.1 Evaluation of angiogenesis 
Angiogenesis or neovascularization refers to blood vessel formation in adults. It arises both is 
physiologic scenarios, such as wound healing and in pathologic processes, such as solid tumor 
development and metastasis (Folkman, 2003; Folkman, 2007), so that angiogenesis is one of the 
“hallmarks of cancer” designed by Hanahan and Weinberg in 2011. In light of these considerations, 
drugs targeting tumor vasculature can be regarded as a potential strategy in the therapy of tumors. 
Antiangiogenic agents have provided only modest benefit as monotherapy, whereas their use in 
combination with conventional cytotoxic chemotherapies has lead to maximal benefit because such 
combinations would destroy two separate compartments of tumors, cancer cells and endothelial 
cells (Gasparini et al., 2005; Volk et al., 2008). On the other hand, tumor vasculature may influence 
the delivery and effectiveness of anticancer therapy (Yu et al., 2002). 
 
The major goal of an antiangiogenic therapy is the reduction of the number of vessels. The 
measurement of angiogenesis is inherently difficult since it is a dynamic process. The vast majority 
of studies have focused so far on the product of angiogenesis, the microvessel density (MVD) 
(Hasan et al., 2000). The assessment of MVD in “vascular hot spots” with the aid of 
immunohistochemistry (IHC) for endothelial cells is the conventional method for evaluating 
angiogenesis in human oncology, but also other morphometric parameters, such as the 
immunolabelled endothelial area (EA) can be evaluated with the aid of digital image analysis (DIA). 
 
Another feature is vascular morphology. Tumor vasculature is generally structurally and 
functionally abnormal (Jain, 2005), characterized by leaky, tortuous, dilated and saccular vessels, 
with decreased pericyte coverage and abnormal basement membrane, due to an imbalance 
between proangiogenic and antiangiogenic factors (McDonald and Choyke, 2003; Thorpe, 2004; 
Baluk et al., 2005). As a consequence, tumor blood flow is impaired, thus resulting in high 
interstitial fluid pressure, hypoxic regions within the tumor, acidosis and impaired drug delivery 
(Jain,2005; Hagendoorn et al., 2007). 
 
An additional parameter that could be assessed after vessel number and morphology is vascular 
maturity, in which pericytes are involved. Pericytes are long, slender, plastic cells of mesenchymal 
origin that have long been regarded as supporting cells. Pericytes do express protein typical of 
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contractile cells, such as smooth muscle-specific isoforms of actin and myosin (Díaz-Flores et al., 
1991) and are closely apposed to the outer surfaces of the endothelial tubes in normal tissue 
vasculature, thus providing mechanical and physiologic support (Hirschi and D’Amore, 1996; 
Gerhardt and Betsholtz, 2003). Tumor-associated vasculature, in contrast, generally lacks 
appreciable coverage by these auxiliary cells. 
 
Traditionally, intra-tumoral microvessels can be identified by immunostaining of endothelial cells 
with specific antibodies, such as CD31, a pan-endothelial marker that can be used on paraffin 
sections. CD31, also known as “platelet endothelial cell adhesion molecule-1” (PECAM-1), can be 
found on the surface of endothelial cells and to a slightly lesser extent on platelets and leukocytes.  
Another usefully applied antibody is Factor VIII-related antigen (FVIIIra), also known as von 
Willebrand factor (vWF), synthesized by endothelial cells and megakaryocytes and mediating 
platelet adhesion to the walls of injured vessels. Immunohistochemical detection of CD31 and 
FVIIIra-positive vessels has been extensively used to quantify angiogenesis of xenograft tumors in 
immunodeficient animal models carrying various human tumor cell loads (Vanzulli et al., 1997; 
Fulzele et al., 2006; Muruganandham et al., 2006; Ragel et al., 2007), although the superiority of 
CD31 over FVIIIra as a marker for angiogenesis in various xenograft models has recently been 
established (Wang et al., 2008). 
 
Beside blood vessels, also lymphatics can be highlighted by immunohistochemistry and several 
specific markers have been identified. These include VEGFR-3, the tyrosine kinase receptor for 
vascular endothelial growth factor (VEGF)-C and VEGF-D (Kaipainen et al., 1995; Joukov et al., 
1996; Achen et al., 1998); podoplanin, a glomerular podocyte membrane mucoprotein 
(Breiteneder-Geleff et al., 1999); Prox-1, the homebox gene product that is involved in 
developmental regulation of the lymphatic system (Wingle and Oliver, 1999); a hyaluronan cell 
surface receptor on lymphatic endothelial cells, LYVE-1 (Jackson et al., 2001) and desmoplakin 
(Ebata et al., 2001). 
 
The evaluation of angiogenesis is part of published paper by Rovida et al.(2013) listed in Appendix 
1 and examples of studies centered on angiogenesis evaluation I performed over my 3-year-PhD 
period are reported below. 
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Experiment II -Evaluation of MVD in pediatric sarcoma xenografts 
In collaboration with IRCCS, Istituto Nazionale dei Tumori of Milan the effects of several preclinical 
angiogenesis inhibitors were tested on pediatric sarcomas xenografts. 
 
The aim of this study was to evaluate the effects of inhibitors of pathways mediated by angiogenic 
factors, including bFGF and VEGF family members, on tumor MVD in pediatric 
rhabdomyosarcoma cell lines (Exp. A and Exp. B) and in Ewing’s sarcoma cell line SK-N-MC (Exp. 
C). 
 
Material and Methods 
Exp. A -Nude CD1 Swiss female mice were injected subcutaneously with human 
rhabdomyosarcoma cells (RD) and divided into different groups of treatment: 
-control mice (CRL, mice 1, 5, 9, SS); 
-mice treated with test inhibitor (Inhib1, mice 1, 2, 5, 7). 
 
Exp. B -Nude CD1 Swiss female mice were injected subcutaneously with human 
rhabdomyosarcoma cells (RD) and divided into different groups of treatment: 
-control mice (CRL, mice 1, 2, 3, 4, 5, 6, 7, 8); 
-mice treated with test inhibitor (Inhib 1, mice 9, 10, 11, 14, 15, 16); 
-mice treated with Sorafenib (SORAFENIB, mice 18, 19, 20, 21, 22, 24). 
 
Exp. C - Nude CD1 Swiss female mice were injected subcutaneously with human Ewing’s sarcoma 
cells (SK-N-MC) and divided into different groups of treatment: 
-control mice (CRL, mice 2, 3, 4, 6, 7); 
-mice treated with test inhibitor, early treatment (Inhib1 early, mice 3, 5, SS); 
-mice treated with test inhibitor, late treatment (Inhib1 late, mice 1, 2, 4). 
 
Overall, excised tumor xenografts and adjacent tissues were routinely formalin fixed and paraffin 
embedded. To assess the extent of tumor angiogenesis, 4 µm sections from each tumor xenograft 
were immunostained with a primary rat monoclonal antibody against CD31 (PECAM) antigen 
(Dianova; clone SZ31). For each sample, serial sections incubated with a 10% solution of normal 
goat serum served as negative controls. For further information a detailed list of all primary 
antibodies and immunohistochemical procedures tested are reported in Table n° 15 at the end of 
Chapter 1. The number of CD31-positive vascular outlines were counted using the ImageJ analysis 
program (http://rsb.info.nih.gov/ij/) in three 200x microscopic fields randomly selected throughout 
the neoplastic tissue, avoiding necrotic areas and the capsule. 
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Results 
Results regarding MVD from the 3 experiments are reported in Tables 4 to 6.  
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Tab. 4. Results regarding MVD in Exp. A. 
Exp Sample Field #1 Field #2 Field #3 tot mean 
A 
1 CTR 4 3 2 9 3 
5 CTR 2 7 3 12 4 
9 CTR 15 9 6 30 10 
SS CTR 6 22 19 47 15,7 
Mean       24,5 8,2 
1 Inhib1 4 4 5 13 4,3 
2 Inhib1 5 6 14 25 8,3 
5 Inhib1 0 0 0 0 0 
7 Inhib1 6 8 10 24 8 
Mean       15,5 5,2 
 
Tab. 5. Results regarding MVD in Exp. B. 
 
Exp Sample Field #1 Field #2 Field #3 tot mean 
B 
1 CTR 9 5 6 20 6,7 
2 CTR 9 6 6 21 7 
3 CTR 6 4 7 17 5,7 
4 CTR 15 10 13 38 12,7 
5 CTR 21 12 10 43 14,3 
6 CTR 11 9 9 29 9,7 
7 CTR 17 9 5 31 10,3 
8 CTR 9 7 18 34 11,3 
Mean       29,1 9,7 
9 Inhib1 17 4 10 31 10,3 
10 Inhib1 6 13 5 24 8 
11 Inhib1 3 6 6 15 5 
14 Inhib1 8 4 10 22 7,3 
15 Inhib1 5 4 7 16 5,3 
16 Inhib1 2 11 7 20 6,7 
Mean       21,3 7,1 
18 Sorafenib 9 7 6 22 7,3 
19 Sorafenib 4 2 3 9 3 
20 Sorafenib 4 6 6 16 5,3 
21 Sorafenib 6 6 3 15 5 
22 Sorafenib 1 5 3 9 3 
24 Sorafenib 8 6 1 15 5 
Mean       14,3 4,8 
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Tab. 6. Results regarding MVD in Exp. C. 
Exp Sample Field #1 Field #2 Field #3 tot mean 
C 
2 CTR 
3 CTR 14 15 8 37 12,3 
4 CTR 9 20 17 46 15,3 
6 CTR 10 6 13 29 9,7 
7 CTR 5 11 10 26 8,7 
Mean   
  
34,5 11,5 
3 Inhib1 early 
5 Inhib1 early 5 14 4 23 7,7 
SS Inhib1 early 2 6 1 9 3 
Mean   
  
16 5,3 
1 Inhib1 late 4 4 8 16 5,3 
2 Inhib1 late 
4 Inhib1 late 6 16 12 34 11,3 
Mean   
  
25 8,3 
 
Exemplificative pictures of immunohistochemical staining are provided in Figures 7 and 8. 
 
Fig. 7. Randomly selected 200x field from a CRL animal from Exp. A. 
Note the large numbers of CD31-positive vessels. 
  
  
 
Fig. 8. Randomly selected 200x field from an animal from Exp. A 
treated with HPA-inib. Note the reduced number of CD31-positive 
vessels compared to CRL mouse. 
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Comments 
Overall, a decrease in the number of vessels in treated groups was noticed compared to control 
ones.  
 
In experiment C, Sorefenib was additionally tested. Sorafenib is a known inhibitor of angiogenesis, 
through inhibition of several receptor tyrosine kinases, such as VEGFR and PDGFR, which 
mediate the signaling of pro-angiogenic factors. 
 
In conclusion, the expected role of the tested angiogenesis inhibitor and Sorafenib in decreasing 
microvessel density in examined pediatric sarcoma xenograft models was confirmed by this pivotal 
study. 
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Experiment III- Evaluation of vascular maturity in an allograft model of 3LL 
In collaboration with Istituto Mario Negri of Milan the effects of Sunitinib on MVD and vascular 
maturity were assessed on murine pulmonary carcinoma Lewis Lung (3LL) implanted 
intramuscularly in mice. Please note this model is not a human xenograft, but an allograft model. 
The pathological approach to the evaluation of the samples would be identical if applied to a 
xenograft model. 
 
The aims of this study were to evaluate MVD and vessel maturation of 3LL implanted in the tibial 
muscle of mice. 
 
Material and Methods 
C57/BL6 mice were injected within the tibial muscle with 3LL cell line. The experiment was 
performed twice and mice were divided into control group and animals treated with Sunitinib. To 
assess vascular maturity, pericyte coverage of blood vessels was investigated through double 
immunofluorescence staining with CD31 and SMA and digital image analysis. 4 µm sections from 
each tumor allograft were immunostained with a primary rat monoclonal antibody against CD31 
(PECAM) antigen (Dianova; clone SZ31) and with a primary rabbit polyclonal antibody against 
Smooth muscle actin (LabVision; RB-9010). Sections were then incubated with Alexa fluor anti-rat 
and Alexa fluor anti-rabbit dyes. For each sample, serial sections incubated with a 10% solution of 
normal goat serum served as negative controls. The number of CD31-positive vascular outlines 
(green fluorescence) and the number of CD31 and SMA-positive vascular outlines (green and red 
fluorescence) were counted using the ImageJ analysis program (http://rsb.info.nih.gov/ij/) in five 
200x microscopic fields randomly selected throughout the neoplastic tissue. 
 
Results 
Results are summarized in Table 7. 
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Tab. 7. Numbers of CD31 and CD31 and SMA-positive vessels within 3LL allograft model. 
Exp Group Sample 
Field 
#1 
CD31 
Field #1 
CD31 
and 
SMA 
Field 
#2 
CD31 
Field #2 
CD31 
and 
SMA 
Field 
#3 
CD31 
Field #3 
CD31 
and 
SMA 
Field 
#4 
CD31 
Field #4 
CD31 
and 
SMA 
Field 
#5 
CD31 
Field #5 
CD31 
and 
SMA 
tot 
CD31 
mean 
CD31 
tot 
CD31 
and 
SMA 
mean 
CD31 
and 
SMA 
1 
SUNITINIB 
#326 11 0 7 0 6 0 15 0 29 0 68 13,6 0 0 
#327 14 0 14 0 7 0 20 0 17 0 72 14,4 0 0 
#403 13 0 14 0 16 0 16 1 11 3 70 14 4 0,8 
#417 15 0 11 0 12 0 15 0 16 0 69 13,8 0 0 
#422 18 0 16 0 10 0 9 0 15 0 68 13,6 0 0 
mean 
          
69,4 13,9 0,8 0,2 
CRL 
#338 43 0 28 0 33 0 34 0 24 0 162 32,4 0 0 
#404 23 0 33 0 15 0 19 1 17 0 107 21,4 1 0,2 
#408 24 0 35 0 22 0 8 0 14 0 103 20,6 0 0 
#423 45 0 25 0 23 0 48 0 48 0 189 37,8 0 0 
#432 45 0 51 0 41 1 56 0 46 0 239 47,8 1 0,2 
mean 
          
160 32 0,4 0,1 
2 
SUNITINIB 
#342 15 0 13 1 8 0 12 1 14 0 62 12,4 2 0,4 
#352 20 0 14 0 19 0 5 0 15 0 73 14,6 0 0 
#361 10 0 8 0 7 0 8 1 5 0 38 7,6 1 0,2 
mean 
          
57,7 11,5 1 0,2 
CRL 
#306 46 0 56 0 28 0 49 0 52 0 231 46,2 0 0 
#847 31 0 38 0 33 0 47 0 38 0 187 37,4 0 0 
#859 34 0 38 0 30 0 29 0 60 0 191 38,2 0 0 
mean 
          
203 40,6 0 0 
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Exemplificative pictures are provided in Figures 9 to 11. 
 
Fig. 9. 200x randomly selected field with CD31-positive endothelial 
cells. 
  
  
 
Fig. 10. Same field of Fig. 9 with a SMA-positive vascular outline. 
  
  
 
Fig. 11. This picture is obtained by merging of the two previous 
Figures. 
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Comments 
Results obtained from 2 different experiments after Sunitinib-treatment recapitulate those reported 
by current literature, with Sunitinib resulting in a reduction of MVD and in an increased pericyte 
vascular coverage, in the context of vascular normalization after treatment of tumors with 
angiogenesis inhibitors (Goel et al., 2011; Griffioen et al., 2012).  
 
In conclusion, not only a reduction in MVD, but also the so-called “normalization” of residual 
vessels were confirmed by these two experiments after pharmacological treatment. Jain (2005) 
hypothesized that antiangiogenic agents can transiently “normalize” the abnormal structure and 
function of tumor vasculature, thus making the delivery of oxygen and chemotherapeutic drugs 
more efficient. Changes in tumor microenvironment, with a decreased microvessel density and 
vessel area, and in vessel morphology, with less leaky, less dilated, less tortuous vessels with a 
normal basement membrane and increased pericyte coverage, decreased interstitial fluid pressure 
and hypoxia after antiangiogenic/VEGF therapy have been demonstrated by several investigators 
(Wildiers et al., 2003; Winkler et al, 2004; Tong et al., 2004; Dickson et al, 2007) and were 
confirmed by the aforereported results. 
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1.3.2 Evaluation of aberrant mitoses 
The evaluation of aberrant mitoses is part of published papers by Colombo et al.(2012) and by 
Pilkington-Miksa et al.(2012) listed in Appendix 1 and an example of a study centered on this type 
of evaluation is reported below. 
 
Experiment IV-Evaluation of aberrant mitoses 
In collaboration with IRCCS, Istituto Nazionale dei Tumori of Milan the effects of Paclitaxel in 
comparison with two novel drugs (Ligand 1 and of Compoud 21) were tested on subcutaneous 
xenografts of human ovarian carcinoma. 
 
Briefly, Paclitaxel (PTX) is an anti-neoplastic drug known to arrest cells in mitosis. No information 
regarding Ligand 1 and Compoud 21 were provided. 
 
The aim of this study was to evaluate the effect of Paclitaxel, Ligand 1 and Compound 21 on 
mitotic index and mitotic morphology in subcutaneous xenografts of human ovarian carcinoma. 
 
Material and Methods 
Cisplatin-resistant human ovarian carcinoma cell lines (IGROV-1/Pt1) were subcutaneously 
injected in nude athymic (nu/nu) female mice. Mice were divided in the following groups of 
treatment: 
-control mice (CRL, mice 1, 2, 3, 4); 
-mice treated with Ligand 1 (mice 5, 6, 7, 8); 
-mice treated with Compound 21 (mice 9, 10, 11, 12); 
-mice treated with Paclitaxel (PTX, mice 13, 14, 15, 16). 
Four µm sections from each tumor xenograft were routinely stained with Hematoxylin-Eosin (HE) 
and evaluated under a light microscope. Mitoses were evaluated in three randomly selected 400x 
fields within the bulk of the xenografts, avoiding areas of necrosis and hemorrhage. The total 
number of mitoses and the mean value for each sample were evaluated. Furthermore, mitoses 
were distincted in “normal” and “aberrant”, considering in this latter class both small condensed 
hyperchromatin nuclei and large cells composed of a nuclear envelope around individual clusters 
of misaggregated chromosomes (mitotic catastrophe), according to Portugal et al.(2010). The ratio 
between the number of aberrant mitoses and total number of mitoses was evaluated. The 
evaluation of mitoses was performed in a blind fashion and only afterwards data were associated 
with corresponding mice. 
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Results 
The number of mitoses further classified as “normal” (N) and “aberrant” (A) observed in the 
different groups of treatment is reported in Table 8. 
 
Tab. 8. The number of normal, aberrant and total mitoses is reported for each examined animal. 
Group Sample #1 #2 #3 mean tot N A TOT N A TOT N A TOT 
CRL 
#1 3 0 3 8 0 8 1 0 1 4 12 
#2 6 0 6 6 0 6 2 0 2 4,7 14 
#3 4 0 4 11 2 13 3 1 4 7 21 
#4 4 1 5 6 0 6 5 0 5 5,3 16 
Mean 5,2 15,7 
Ligand1 
#5 8 1 9 6 0 6 2 1 2 5,7 17 
#6 3 0 3 8 1 9 6 0 6 6 18 
#7 3 1 4 3 0 3 4 0 4 3,7 11 
#8 0 3 3 6 0 6 9 0 9 6 18 
Mean 5,3 16 
Compound21 
#9 5 22 27 4 2 6 0 62 62 31,7 95 
#10 0 43 43 0 30 30 0 17 17 30 90 
#11 2 3 5 9 2 11 7 7 14 10 30 
#12 6 9 15 9 3 12 2 3 5 10,7 32 
Mean 20,6 61,7 
PTX 
#13 5 5 10 4 8 12 9 4 13 11,7 35 
#14 3 2 5 5 9 14 3 6 9 9,3 28 
#15 8 0 8 0 7 7 0 2 2 5,7 17 
#16 0 13 13 1 3 4 0 2 2 6,3 19 
Mean 8,2 24,7 
 
The ratio between aberrant and total number of mitoses is reported in Table 9 and summarized in 
Figure 12. An exemplificative picture of an aberrant mitosis is shown in Figure 13. 
 
Tab.9. Ratio between normal vs aberrant mitoses. 
Group Sample ratio field #1 ratio field #2 ratio field #3 mean 
CRL 
#1 0 0 0 0 
#2 0 0 0 0 
#3 0 0,15 0,25 0,13 
#4 0,2 0 0 0,1 
mean 0,1 
Ligand1 
#5 0,1 0 0,5 0,2 
#6 0 0,1 0 0,03 
#7 0,25 0 0 0,08 
#8 1 0 0 0,3 
mean 0,2 
Compound21 
#9 0,8 0,3 1 0,7 
#10 1 1 1 1 
#11 0,6 0,2 0,5 0,4 
#12 0,6 0,25 0,6 0,5 
mean 0,7 
PTX 
#13 0,5 0,7 0,3 0,5 
#14 0,4 0,6 0,7 0,6 
#15 0 1 0 0,3 
#16 1 0,75 1 0,9 
mean 0,6 
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Fig. 12. Ratio between normal vs aberrant mitoses in different groups of treatment. 
 
 
 
Fig. 13. Example of an aberrant mitosis from a mouse treated 
with Paclitaxel, HE. 
 
Comments 
Histological analysis highlighted an exceedingly higher number of mitoses in the group treated with 
Compound 21, compared to other ones. Furthermore, the majority of the mitoses observed in this 
group and in the group treated with PTX were aberrant. 
 
The finding that the majority of mitoses observed in PTX-treated group were aberrant is consistent 
with the mechanism of action of the drug (Roninson et al., 2001; Portugal et al., 2010; Matson and 
Stukenberg, 2011). Paclitaxel is a spindle poison that arrests cells in mitosis, binding to tubulin 
within existing microtubules and stabilizing the polymer. When incubated with spindle poisons, the 
number of mitosis dramatically increases, with cells entering mitosis, but failing to exit and 
assuming an aberrant morphology, the so called “mitotic catastrophe” (Portugal et al., 2010), which 
is characterized by a nuclear envelope around individual clusters of misaggregated chromosomes. 
 
In conclusion, the expected role of Paclitaxel was confirmed by this small pivotal study. 
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1.3.3 Evaluation of apoptoses 
Apoptosis is a pathway of cell death that is induced by a tightly regulated program in which cells 
destined to die activate enzymes that degrade the cells’ own nuclear DNA and nuclear and 
cytoplasmic proteins. 
 
The evaluation of apoptoses is part of published paper by Lopergolo et al. (2013) listed in 
Appendix 1 and an example of a study centered on this type of evaluation is reported below. 
 
Experiment V- Evaluation of apoptoses in medullary thyroid carcinoma xenograft 
In collaboration with IRCCS, Istituto Nazionale dei Tumori of Milan the number of apoptosis was 
evaluated in human medullary thyroid carcinoma xenografts. 
 
The aim of this study was to evaluate the effect of Cisplatin and Sunitinib on the number of 
apoptoses observed in human medullary thyroid carcinoma xenografts. 
 
Material and methods 
Human medullary thyroid carcinoma cells (MZ CRC-1 cells) were injected subcutaneously in SCID 
mice and sacrificed at day 38. Mice were divided into different groups of treatment: 
-control mice (CRL, mice 1, 2, 3); 
-mice treated with Cisplatin (mice 4, 5, 6); 
-mice treated with Sunitinib (mice 7, 8, 9); 
-mice treated with a combination of Cisplatin and Sunitinib (mice 10, 11, 12). 
 
Four µm sections from each tumor xenograft were routinely stained with Hematoxylin-Eosin (HE) 
and evaluated under a light microscope. Furthermore, to quantify the number of apoptoses, 4 µm 
sections from each tumor xenograft were immunostained with a primary rabbit polyclonal antibody 
against the active form of caspase (Cell Signalling, clone Asp175). For each sample, serial 
sections incubated with a 10% solution of normal goat serum served as negative controls. The 
ratio between the total number of caspase positive-neoplastic cells and the total number of 
neoplastic cells (apoptotic index) was calculated using the ImageJ analysis program 
(http://rsb.info.nih.gov/ij/) in six 400x microscopic fields randomly selected within the bulk of the 
xenograft, avoiding necrotic areas and the capsule. Focally clustered labeled nuclear “dust” (free 
apoptotic bodies) were counted as 1 cell. 
 
Results 
Analysis of HE stained sections, with peculiar emphasis on the evaluation of apoptoses is reported 
in Table 10. 
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Tab. 10. Histopathological parameters from Experiment V. 
Group Sample 
Prevalent 
pattern of 
growth 
Necrosis Stroma Peripheral invasion Capsule 
Mitoses Apoptoses 
in 3 HPF Mean Tot in 3 HPF Mean Tot 
Crl 
#1 lobules 1 2 0 1 10;11;7 9,3 28 0;3;0 1 3 
#2 solid 1 1 0 1 3;7;6 5,3 16 3;2;1 2 6 
#3 solid 1 2 0 1 10;4;5 6,3 19 1,7;2 3,3 10 
Mean   1 1,7 0 1  7 21  2,1 6,3 
Cisplatin 
#4 solid areas 1 2 0 1 3;3;2 2,7 8 27;9;17 17,7 53 
#5 lobules 1 2 0 1 1;5;0 2 6 16;24;18 19,3 58 
#6 solid areas 1 2 0 1 1;0;1 0,7 2 30;27;15 24 72 
Mean   1 2 0 1  1,8 5,3  20,3 61 
Sunitinib 
#7 solid areas 3 2 0 1 0;2;4 2 6 7;10;13 10 30 
#8 solid 1 1 0 1 3,3;1 2,3 7 6;11;1 6 18 
#9 lobules 1 2 0 1 1;1;4 2 6 6;8;7 7 21 
Mean   1,7 1,7 0 1  2,1 6,3 
 
7,7 23 
Cisplatin + 
Sunitinib 
#10 solid 1 2 0 1 0;0;2 0,7 2 39;67;23 43 129 
#11 solid 2 2 0 1 2;0;0 0,7 2 40:17;50 35,7 107 
#12 solid 1 3 0 1 0;0;1 0,3 1 94;90;55 80 239 
Mean   1,3 2,3 0 1  0,6 1,7 
 
52,9 158,3 
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Aforereported results are summarized in Table 11. 
 
Tab. 11. Mean histopathological scores and mean numbers of mitoses and apoptoses shown in Tab.10. 
Group necrosis stroma mitoses apoptoses 
mean tot mean tot 
Crl 1 1,7 7 21 2,1 6,3 
Cisplatin 1 2 1,8 5,3 20,3 61 
Sunitinib 1,7 1,7 2,1 6,3 7,7 23 
Cisplatin + Sunitinib 1,3 2,3 0,6 1,7 52,9 158,3 
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Results obtained by Cleaved caspase-3 immunohistochemistry are reported in Table 12 and 
exemplificative pictures are provided in Figures 14 and 15. 
 
Tab. 12. Immunohistochemical evaluation of apoptoses. 
Group Sample Field #1 #2 #3 #4 #5 #6 tot apoptotic index 
CRL 
#1 
pos 
nuclei 1 5 10 2 5 7 30 0,01 tot 
nuclei 327 340 424 329 371 431 2222 
#2 
pos 
nuclei 3 0 2 8 0 4 17 0,01 tot 
nuclei 365 380 430 368 316 329 2188 
#3 
pos 
nuclei 2 2 3 1 5 5 18 0,01 tot 
nuclei 397 362 377 368 360 337 2201 
Mean 0,01 
CISPLATIN 
#4 
pos 
nuclei 19 16 9 37 10 17 108 0,05 tot 
nuclei 382 341 368 317 244 315 1967 
#5 
pos 
nuclei 29 16 53 13 5 10 126 0,07 tot 
nuclei 423 285 392 182 198 242 1722 
#6 
pos 
nuclei 48 20 14 22 16 15 135 0,06 tot 
nuclei 400 319 378 371 294 290 2052 
Mean 0,06 
SUNITINIB 
#7 
pos 
nuclei 5 8 16 22 3 21 75 0,04 tot 
nuclei 297 333 330 310 258 352 1880 
#8 
pos 
nuclei 6 16 4 6 4 3 39 0,02 tot 
nuclei 353 384 240 268 239 319 1803 
#9 
pos 
nuclei 9 5 1 15 6 8 44 0,02 tot 
nuclei 261 321 320 325 280 229 1736 
Mean 0,03 
CISPLATIN + 
SUNITINIB 
#10 
pos 
nuclei 39 28 22 26 10 44 169 0,09 tot 
nuclei 375 317 311 331 151 336 1821 
#11 
pos 
nuclei 29 24 27 32 43 42 197 0,12 tot 
nuclei 264 305 274 223 277 302 1645 
#12 
pos 
nuclei 50 57 65 28 45 48 293 0,16 tot 
nuclei 293 398 337 236 267 262 1793 
Mean 0,12 
 
28 
 
Fig. 14. Randomly selected high power field from sample #3 (control). 
Note the exceedingly low number of caspase-positive nuclei, stained 
in brown against the blue-counterstained ones. Cleaved-caspase 3 
immunohistochemistry, 400x. 
  
  
 
Fig. 15. Randomly selected high power field from sample #12 
(Cisplatin+Sunitinib). Note the high number of caspase-positive 
nuclei, stained in brown against the blue-counterstained ones. 
Cleaved-caspase 3 immunohistochemistry, 400x. 
 
Comments 
Results obtained by immunohistochemistry recapitulated those obtained by evaluation of 
hematoxylin and eosin-stained sections. The highest number of apoptoses was observed in mice 
treated with both Cisplatin and Sunitinib. 
 
Sunitinib is supposed to inhibit Ret, a proto-oncogene that is known to be mutated in medullary 
thyroid carcinomas (Nicolini et al., 2011), whereas Cisplatin elicits apoptosis both via the intrinsic 
(mitochondrial) pathway, causing DNA crosslinking and the extrinsic one, via CD95 (Fas) pathway. 
In conclusion, the exceedingly higher number of apoptosis observed in the group treated with the 
two combined drugs support the hypothesis of a synergic action between them. 
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1.4 -Matrigel plug assay 
Briefly, the matrigel plug assay is based on the subcutaneous injection of an extract of basement 
membrane proteins (Matrigel) containing cells or substances to be tested. Matrigel is a soluble and 
sterile compound derived from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in 
ECM proteins. Its major component is laminin, followed by collagen IV, heparan sulfate 
proteoglycan and entactin. After subcutaneous injection, Matrigel solidifies to form a plug that can 
be recovered after approximately 7-21 days in the animal and examined histologically (Passaniti et 
al., 1992). Matrigel supports cell morphogenesis, differentiation and tumor growth and furthermore 
growth factors and compounds can be added, thus enhancing cell growth, differentiation and/or 
angiogenesis. 
 
An example of a study with Matrigel is reported below. 
 
Experiment VI - Evaluation of an anti-tumor drug in a Matrigel plug assay 
In collaboration with Istituto Mario Negri of Bergamo (BG) an experiment was designed to 
investigate the role of an anti-tumor drug of marine origin. 
 
Tested compound is an antitumoral agent of marine origin that is reported to block the cell cycle 
and interfere with inducible gene transcription and to induce cytotoxic effects on monocytes and 
macrophages. According to current literature, a reduction in the number of tumor vessels and of 
F4/80-positive macrophages have been described after its administration (Germano et al., 2010). 
 
The aim of this study was to evaluate vascular and lymphatic vessels and macrophagic infiltrate 
after administration of tested compound in mice injected with Matrigel alone or Matrigel added with 
bFGF. 
 
Please note that no neoplastic cells either of human or murine origin were implanted within the 
Matrigel in this experiment, thus this study is different from the other ones presented. 
 
Material and Methods 
Mice were divided in different groups of treatment as follows: 
-mice injected with empty matrigel (mice Crl - 1, 2, 3, 4, 5, 6, 7); 
-mice injected with matrigel added with bFGF (mice Crl + 1, 2, 3, 4, 5, 6, 7); 
-mice injected with matrigel and treated with tested compound, administered twice a day for 3 days 
(q2X3) at the dose of 0.1 mg/kg (mice 376, 377, 380, 381, 389, 393); 
-mice injected with matrigel and treated with tested compound, administered once a day for 5 days 
(q1X5) at the dose of 0.1 mg/kg (mice 353, 356, 357, 358, 362, 363, 366). 
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Mice were sacrificed and the whole pellet encompassing skin and deep muscles was collected and 
fixed in 10% buffered formalin. Pellets were processed and embedded in paraffin, oriented along a 
transverse cut section and cut into serial sections of four-µm thickness and used for 
immunohistochemical analysis. CD31, LYVE-1 and F4/80 were the immunohistochemical markers 
used in this study to detect blood vessels, lymphatics and macrophagic infiltrate respectively. To 
establish microvessel density, area and morphology, formalin-fixed sections from each pellet were 
immunostained with the rat monoclonal anti-mouse CD31 antibody, a specific marker for 
endothelial cells (Dianova). The reaction was revealed by incubating the sections with 3,3’-
diaminobenzidine (Vector Laboratories, Burlingame, CA). Hematoxylin counterstaining was done. 
Vascular hotspots (three fields in each sample when possible) were selected at 200X within the 
matrigel. These areas generally corresponded to the periphery of the pellet. 
 
To estabilish lymphatic vessel density, area and morphology, formalin-fixed, paraffin-embedded 
sections from each group were immunostained with the rabbit polyclonal Lyve-1 antibody, a 
specific marker for lymphatic vessels (AbCam, clone 14917). The reaction was revealed by 
incubating the sections with 3,3’-diaminobenzidine (Vector Laboratories, Burlingame, CA). 
Hematoxylin counterstaining was performed. 
 
Hotspots (three fields in each sample when possible) were selected at 200X within the matrigel. 
These areas generally corresponded to the periphery of the pellet.  
 
Morphometric analysis for both vascular and lymphatic vessels were performed with Image-Pro 
Plus software. 
 
The parameters collected were: 
• vessel number (object count); 
• vessel area (expressed in µm2); 
• mean vessel diameter (expressed in µm, is the average length of diameters measured at 2 
degrees intervals and passing through object’s centroid). 
 
For the assessment of the number of macrophages, five 200x randomly selected fields were 
evaluated. 
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Results 
Results regarding evaluation of both blood and lymphatic vessels are summarized in Table 13. 
 
Tab. 13. Number of blood and lymphatic vessels in the groups of mice. 
Group CD31 LYVE-1 
number area diameter number area diameter 
matrigel 5 555 6.1 1.4 28.7 2.6 
matrigel with bFGF 26.1 1759 5.8 2.3 63 2.6 
Tested compound 0.1 mg/kg Q2X3 9.7 1256 13.5 1 27.7 2 
Tested compound 0.1 mg/kg Q1X5 4.6 481 4.8 0.2 4.8 0.5 
 
Macrophagic infiltrate was evaluated within matrigel with bFGF and tested compound administered 
0.1 mg/kg Q1X5 groups. Mean values are reported in Table 14 and exemplificative pictures in 
Figures 16 to 19. 
 
Tab. 14. Mean numbers of macrophages within examined 2 groups. 
Group n° of macrophages  
Matrigel with bFGF MEAN 16 
Matrigel with tested compound 0.1 mg/kg Q1X5 MEAN 8,3 
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Fig. 16. Matrigel with bFGF, F4/80 IHC, 200x. Fig. 17. Matrigel with bFGF, F4/80 IHC, 200x, 
quantification of macrophagic infiltrate. 
  
  
  
Fig. 18. Matrigel with tested compound 0.1 mg/kg 
Q1X5, F4/80 IHC, 200x. 
Fig. 19. Matrigel with tested compound 0.1 mg/kg 
Q1X5, F4/80 IHC, 200x, quantification of 
macrophagic infiltrate. 
 
Comments 
Obtained results mirrored those reported by current literature, with tested compound acting as an 
antiangiogenic drug (Allavena et al., 2013) and also reducing the number of F4/80-positive 
macrophages (Germano et al., 2010). 
 
In conclusion, results obtained by this small pivotal study confirmed those reported by current 
literature and matrigel turned out to be a valid tool. 
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1.5 -Humane endpoints 
There are ethical, scientific and legal reasons for ensuring that adverse effects are minimized in 
experimental animals. All experiments should incorporate the 3 Rs, as defined by Russell and 
Burchin in 1959: replacement (of animals with other, non-sentient material or with animals of lower 
sentience); reduction (of numbers of animals used) and refinement (of technique, “to reduce to an 
absolute minimum the amount of distress imposed on those animals that are still used”). 
 
In all cases, experimental designs and procedures should be tailored to the needs of the specific 
studies and a cross-talk between investigators and veterinary pathologists is strongly encouraged, 
in order to optimize the study set. Furthermore, when possible pilot tumour growth studies using 
small numbers of animals are recommended. Preliminary data derived from these studies would 
facilitate the definition of robust and refined endpoints and nowadays imaging techniques available 
facilitate the development of more defined endpoints for some tumor models. 
 
An “endpoint” is defined as the point at which an experimental animal’s pain and/or distress is 
terminated, minimized or reduced, by taking actions such as killing the animal humanely, 
terminating a painful procedure, or giving treatment to relieve pain and/or distress. Early end points 
reduce non-specific systemic effects and so may increase the precision of the results obtained. 
 
Tumor burden should always be limited to the minimum required for a valid scientific outcome. 
Assessment of the size of superficial tumors using calipers (usually of two diameters at right 
angles) is an easy and definable method and calibration curves should be established as part of 
the characterization of any new tumor system (Workman et al., 1998). For a mouse carrying a 
single tumor, the mean diameter should not normally exceed 1.2 cm or 1.5 cm for therapeutic 
studies. Furthermore, scoring of ulceration, distension of covering tissues and cachexia, defined as 
severe body weight loss, should be incorporated into the endpoints (Workman et al., 2010). 
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1.6 - Conclusive remarks regarding subcutaneous xenografts 
The approach to subcutaneous xenograft starts with a gross evaluation, that can be performed to 
monitor both successful engraftment of the tumor and tumor growth and animal welfare. 
 
A proper collection of the sample is mandatory and marginal excision should be avoided. 
Histopathological examination provides useful information about the pattern of tumor growth, 
cellular morphology, cross-talk between tumor and stroma and intralesional areas of necrosis and 
inflammation and achieved data can be corroborated by further histochemical and 
immunohistochemical investigations. 
 
Examples provided above are far from fully elucidate the potential of immunohistochemistry in the 
characterization of human tumors. Many other antibodies can be profitably used, such as: 
-antibodies to characterize tumor cells and get information about the maintenance of their original 
differentiation (e.g. Vimentin, MyoD1, Desmin, Smooth Muscle Actin and Myoglobin if an original 
muscular differentiation is under investigation); 
-antibodies to characterize the inflammatory infiltrate elicited by tumor growth, taking into account 
data collected from immunodeficient animals may be underestimated; 
-antibodies applied to quantify tumor cell proliferation, such as Ki-67. 
 
A detailed list of the antibodies I used during the PhD period is provided in Table 15.  
 
Tab. 15. Primary antibodies applied in the evaluation of subcutaneous xenografts. 
Antigen Supplier Clonality Clone/code 
n° 
Antigen 
retrieval 
Working 
dilution and 
detection 
system 
Incubation 
time Application 
CD31 Dianova Rat mon SZ31 HIER 1/50 ABC 1h RT microvessel 
number 
Smooth 
muscle 
actin 
LabVision Rb poly #RB-9010 HIER 1/50 Alexa 1h RT microvessel 
maturity 
Cleaved 
caspase-
3 
Cell 
Signaling Rb poly Asp175 HIER 1/2500 ABC 1h RT apoptosis 
Ki67 LabVision Rb mon #RM-9106-S HIER 1/400 ABC 1h RT proliferation 
Lyve-1 Abcam Rb poly ab14917 HIER 1/200 ABC 1h RT lymphatic 
vessels 
F4/80 Serotec Rat mon Cl:A3-1 MCA497G digestion 1/150 ABC 1h RT macrophages 
Rat mon: rat monoclonal; Rb poly: rabbit polyclonal; Rb mon: rabbit monoclonal; HIER: heat-
induced epitope retrieval, 0.01 mol/L citrate buffer pH=6.0; digestion: enzymatic digestion; Digest-
all TM 3 Pepsin solution RTU (Zymed, S. Francisco, USA); ABC: Vector Lab, Vectastain Elite ABC 
kit PK-6100; Alexa: Alexa fluor anti-rabbit dye; 1h RT: one hour at room temperature 
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Chapter 2 - Intraperitoneal xenografts 
2.1 -Introduction 
The evaluation of an intraperitoneal xenograft model is part of a published paper by Oliva et al., 
2012 listed in Appendix 1 and an example of a study centered on i.p. evaluation I performed over 
my 3-year-PhD period is reported below. 
 
Intraperitoneal xenografting is useful in the study of ovarian carcinoma. This approach results in 
consistent involvement of ovaries and uterus, peritoneal dissemination and production of ascites 
(Connolly, 2009). 
 
2.2 – Experiment VII- Intraperitoneal xenograft model of human ovarian carcinoma 
In collaboration with Istituto Mario Negri of Milan a study on the intraperitoneal (i.p.) dissemination 
of HOC 22, a human ovarian carcinoma cell line was designed to investigate Bevacizumab 
combined with chemotherapy on tumor burden. 
 
Epithelial ovarian cancer (EOC) is the leading cause of death for gynecologic malignancy for 
women in the Western countries mainly because the majority of patients are diagnosed at 
advanced stage of disease. Advances in early detection, treatment and prevention are required 
and animal models of ovarian cancer are invaluable tools in these pursuits. 
The aim of this study was to evaluate the contributions of chemotherapy (Paclitaxel, PTX + 
Cisplatin, DDP) and inhibitors of angiogenesis (Bevacizumab, BEV) in controlling spread and 
progression to secondary organs and ascites formation in the peritoneal cavity of mice injected 
with a human high-grade serous ovarian carcinoma (HOC 22). 
 
Material and Methods 
Six- to eight-week-old female NCr-nu/nu mice were injected with 10 x106ascites-derived cell 
suspension of HOC 22 into the peritoneal cavity. Mice were treated with PTX and DDP, singly or in 
association (PTX + DDP). Bevacizumab was administered according to three protocols: a) in 
combination with chemotherapy; b) in combination with chemotherapy and continued after the end 
of the therapy; c) starting 24h after the end of the therapy. Vehicles were administered at the same 
schedule and route as the active compounds. Three HOC22-bearing mice were necropsied at the 
beginning of treatment (randomization) to confirm the presence of tumor in the peritoneal cavity. At 
the end of treatment (interim analysis) four to six mice per group were euthanized and necropsied 
to establish tumor burden and organs involved in the tumor spread. The remaining mice were also 
necropsied at the end of the study (survival). A complete necropsy was performed on each mouse 
and gross findings were recorded and scored (data not shown). Ascites was harvested and the 
volume was recorded for each mouse (Manenti et al, 2005). For histopathological analysis, organs 
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(uterus and ovaries, stomach, small intestine, ileocecocolic valve, large intestine, pancreas, 
kidneys, spleen, liver and gallbladder, diaphragm, heart, lungs and enlarged lymph nodes) were 
sampled and fixed in 10% neutral buffered formalin. After fixation, tissues were processed and 
paraffin-embedded and 4-µm sections were stained with hematoxylin and eosin for microscopic 
examination. 
 
A histological score was used to compare groups. Neoplastic lesions were classified by size as 
follows: 
i. small: up to 10 neoplastic cells; 
ii. medium: from 11 to 100 neoplastic cells;  
iii. big: more than 100 neoplastic cells. 
 
Up to 10 nodules per size category were counted in each organ and a value of 1 was arbitrarily 
assigned to each small neoplastic growth, 2 to each medium one and 4 to big ones. Thus, each 
organ could reach at least 70, except for organs completely effaced by the neoplastic growth, 
which were arbitrarily assigned a score of 100. A different method was applied to the diaphragm, 
which was scored according to the percentage of the organ covered by neoplastic cells, as follows: 
i. 0%, no neoplastic cells detactable;  
ii. 1-25%, assigned a score of 10; 
iii. 25-75%, assigned a score of  40; 
iv. >75%, assigned a score of  70; 
v. >75% with neoplastic cells arranged in several layers or in a nodular mass, 
assigned a score of 100. 
 
Results 
Macroscopically, metastases could be appreciated as whitish nodules as illustrated in Figure 19. 
 
Fig. 19. Example of grossly detectable metastases of HOC 22. 
 
Histologically, HOC 22 metastases were composed of epithelial cells arranged in acini and solid 
areas, with scant to moderate fibrovascular stroma. Cells were polygonal, 10x50µm in diameter 
with pale eosinophilic homogeneous cytoplasm and a central nucleus with vesicular chromatin. 
Mitoses were 4-6 hpf and occasionally atypical. There were intralesional areas of necrosis and 
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hemorrhage and calcium concrements in acinar lumina (psammoma bodies). Multifocally, clusters 
of small mature lymphocytes infiltrated the mass. 
Necropsy on representative mice showed macroscopic reduction of ascites, but more HOC22 
neoplastic aggregates in mice treated with Bevacizumab alone both at interim and killing; reduction 
of tumor masses was observed after chemotherapy. The liver, ovaries and uterus, diaphragm and 
pancreas were the organs most commonly involved in tumor dissemination. 
Results of the histopathological analysis performed at interim are reported in Table 16 and 
summarized in Figure 20. Briefly, at interim analysis, the vehicle group had the highest tumor 
burden and amount of ascites, and mice treated with PTX+DDP+Bev had the lowest ones. The 
interim analysis indicated that Bevacizumab alone reduces ascites formation (undetectable), but 
does not limit tumour burden. However, Bevacizumab added to PTX + DDP (PTX + DDP + Bev) 
reduced both ascites and tumour burden. 
 
Tab.16. Tumor burden and amount of ascites at interim. 
 
Vehicle Bev PTX + DDP PTX + DDP + Bev 
Ascites (ml) 6 / 0,5 / 
Tumor burden 15 17 14 14 
Most affected 
organs 
ovaries/uterus, 
liver, pancreas, 
diaphragm, 
stomach 
ovaries/uterus, 
liver, pancreas, 
lung, kidney, 
diaphragm, 
stomach 
ovaries/uterus, 
liver, pancreas, 
diaphragm 
liver 
 
 
Fig. 20. Tumor burden at interim. 
 
Results of the histopathological analysis performed at killing are reported in Table 17. As expected, 
tumor scores at killing were higher than those at interim analysis, but with the same pattern. The 
tumor burden was highest in the Bevacizumab maintenance group, with minimal ascites (not 
measurable) and a wider range of dissemination than in the other groups. 
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Tab. 17. Tumor burden and amount of ascites at killing. 
 
Bev Bev cont PTX + DDP 
PTX + 
DDP + 
Bev 
PTX + DDP + 
Bev 
cont_stopped 
PTX + DDP + Bev 
cont_maintained 
Ascites 
(ml) 
5,5 0,75 7 7 6 5 
Tumor 
burden 
20 25 19 16 0 0 
 
Exemplificative pictures are provided in Figures 21 and 22. 
 
Fig. 21. Note the >100 neoplastic cells metastasis in the mesentery 
between the liver and the gallbladder and the smaller one in the 
hepatic parenchyma. HE, 25x 
  
  
 
Fig. 22. Massive metastatic invasion of the diaphragm. HE, 50x 
 
Comments 
Data achieved from histological analysis closely recapitulated macroscopic findings and highlighted 
differences among groups in respect of tumor burden and ascites formation. At the doses and 
schedules used, PTX and DDP single agents were not efficacious, whereas the addition of 
Bevacizumab significantly prolonged survival for both combinations. Maintenance treatment with 
Bevacizumab alone inhibited tumour progression and significantly prolonged survival compared 
with Bevacizumab interrupted after 3 weeks. Only the combination of the two chemotherapeutics 
with Bevacizumab in maintenance treatment resulted in tumour-free mice. The triple combination 
(DDP+ PTX + Bev) and maintenance regimens (PTX + DDP + Bev  Bev) were well tolerated, 
with no clinical signs of toxicity throughout the study or significant body weight loss. 
 
In conclusion, dissemination into the peritoneal cavity is the primary route of progression of ovarian 
cancer, and ascites and tumour burden correlated with prognosis. These trials indicate an 
advantage adding Bevacizumab to chemotherapy, which was amplified by a maintenance regimen 
with Bevacizumab after chemotherapy. 
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2.3 - Humane endpoints 
For tumors growing as a suspension into the peritoneal cavity, it is important to establish clear 
criteria to ensure that studies are terminated before animal welfare is compromised (Workman et 
al., 2010). Mice should be monitored twice a week for body weight loss and tumor formation in the 
peritoneal cavity (abdominal distension) and should be euthanized when they become moribund 
(Garofalo et al., 2003). 
 
2.4 - Conclusive remarks regarding intraperitoneal xenografts 
This site is only appropriate for models where ascites is a feature of the natural progression of the 
human cancer, e.g. ovarian carcinoma (Workman et al., 2010).  
 
From the HOC 22 study an overall efficacy of Bevacizumab combined with chemotherapy in 
mouse EOC xenograft models was found. Bevacizumab continued after chemotherapy significantly 
delayed tumour progression in the peritoneal cavity and prolonged survival. Furthermore, 
antiangiogenic agents such as Bevacizumab can be administered over long periods with 
manageable toxicity (Gerber and Ferrara, 2005; Shah et al., 2011). Therefore, it is feasible to use 
antiangiogenic therapy as a maintenance regimen and it can be expected to prevent or delay 
cancer recurrence. As already introduced, it is believed that treatments affecting angiogenesis, 
including bevacizumab, enhance the effect of chemotherapy, by normalizing tumor vasculature, 
lowering interstitial pressures and improving the delivery of cytotoxic agents (Jain, 2005). Based on 
these considerations, vascular “normalization” might explain why bevacizumab in combination with 
chemotherapy was effective in this study. 
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Chapter 3 -Promising metastatic models 
3.1 - Introduction 
The metastatic process is critical in modeling cancer because of its clinical relevance and because 
the majority of human malignant tumors have metastases at the time of diagnosis, either clinically 
evident or micrometastases (Céspedes et al., 2006). The metastatic process can be regarded as a 
succession of steps, including invasion of the ECM, intravasation, survival in circulation, adhesion 
to basement membrane, extravasation, metastatic deposit, angiogenesis and growth. Many mouse 
models do not develop metastases at all or are scarcely metastastic and in the few spontaneous 
models available, metastatic deposits may appear only in a limited numbers of sites, with a very 
long latency (Céspedes et al., 2006). 
 
Metastastic tumors commonly arise within the lung because of the organ’s rich capillary network 
(Harris et al., 2011) that receive the venous blood from all the body. 
 
The evaluation of pulmonary metastases is part of the proceeding production by Castiglioni et 
al.(2013), listed in Appendix 1 and examples of studies centered on the evaluation of metastases I 
performed over my 3-year-PhD period are reported below. 
 
3.2 - Experiment VIII- Pulmonary metastases of a subcutaneous xenograft carcinoma 
In collaboration with IRCCS, Istituto Nazionale dei Tumori of Milan a promising model of carcinoma 
metastasizing to the lungs was investigated. 
 
The flank is commonly used for primary xenografts in mice, but it is rare for these tumors to 
metastasize. 
 
The aim of this study was to develop a reliable spontaneous metastatic murine model with human 
non-small-cell lung cancer (NSCLC) and to characterize the model as to location of the 
spontaneously occurring metastases. 
 
Material and Methods 
Female SCID mice were injected subcutaneously with NSCLC H460 wt cell line and divided in the 
following groups of treatment: 
-control mice injected with H460 wt; 
-mice injected with H460 wt and treated with compound 1 (Cpd 1); 
-mice injected with H460 wt and treated with compound 2 (Cpd 2). 
Mice were sacrificed at day 45 and lungs were formalin fixed and paraffin embedded. Four µm 
sections from each lung were routinely stained with Hematoxylin-Eosin (HE) and evaluated under a 
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light microscope. For a careful examination of metastatic spread to lungs, all lobes of each lung 
were evaluated. A general description of the metastases was provided and a combined score was 
set up, considering the number and the size of metastases. According to their size and based on 
current literature (Sacco et al., 2000), metastases were classified as follows: 
 
-small : < 10 neoplastic cells; 
-intermediate: 10-100 neoplastic cells; 
-large: >100 neoplastic cells. 
 
Arbitrary, a value of 1 was assigned to each small mass, a value of 2 to each medium mass and a 
value of 4 to each large one. The evaluation was performed in a blind fashion and only afterwards 
data were related to corresponding mice. 
 
To confirm the human origin of metastases, selected samples were immunostained with anti-
human MHC class I antibody (Abcam), specifically reacting with human tissues and not with 
murine ones. Furthermore, anti-mouse CD31 (PECAM-1) antibody (Histonova) was also 
performed, in order to highlight the endothelium of vessels and discriminate between intravascular 
emboli and metastases. 
 
Results 
Multifocally alveolar and perivascular interstitium were expanded by densely cellular, nodular, well 
demarcated, unencapsulated masses, composed of polygonal cells approximately 15µm in 
diameter with distinct cell borders, an intermediate N/C ratio and a moderate amount of pale 
eosinophilic finely granular cytoplasm. Nuclei were 10µm in diameter, oval, with marginated 
chromatin and an evident paracentral magenta nucleolus. Anisocytosis and anisokaryosis were 
mild to moderate. There were rare mitoses with bizarre morphology. Occasionally neoplastic cells 
were detectable within vessels (emboli) and/or are embedded in mats of finely fibrillar to beaded 
eosinophilic material (fibrin) and in a finely granular eosinophilic material (secretum).  
Results of the metastatic count are reported in Table 18. 
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Tab.18. Number of pulmonary metastases and score assigned. 
Group Sample N° of 
small met 
N° of 
intermediate met 
N° of 
large met score 
additional 
findings 
Control 
H460 wt 
#1 0 0 4 16 / 
#2 5 5 3 27 / 
#3 0 0 1 4 / 
#4 1 2 4 21 / 
#5 7 4 6 39 / 
#6 1 1 0 3 / 
mean ± d.s. 18,3 ± 13,8 
 
Cpd 1 
#7 0 2 0 4 / 
#8 0 2 0 4 / 
#9 0 0 0 0 / 
#10 1 1 0 3 / 
#11 0 1 1 6 / 
#12 0 1 1 6 / 
mean ± d.s. 3,8 ± 2,2 
 
Cpd 2 
#13 1 6 2 21 Acidophilic 
macrophage 
pneumonia 
#14 6 2 0 10 / 
#15 0 1 0 2 / 
#16 0 0 0 0 / 
#17 2 4 6 34 / 
#18 1 6 2 21 / 
mean ± d.s. 14,7 ± 13 
 
 
Mean values are summarized in Table 19 and exemplificative pictures of hematoxylin and eosin 
and of immunohistochemical markers performed are provided in Figures 23 to 28. 
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Tab. 19. Sum of mean values of pulmonary metastases. 
Group mean ± d.s. 
Control H460 wt 18,3 ± 13,8 
Cpd 1 3,8 ± 2,2 
Cpd 2 14,7 ± 13 
 
   
Fig. 23. Crl H460 wt; HE, 20x. Fig. 24. Crl H460 wt; HE, 40x. Fig. 25. H460 wt treated with 
Cpd2; HE, 20x. 
   
   
 
 
 
Fig. 26. Crl H460 wt; HE, 10x. Fig. 27. Crl H460 wt; anti-
human MHC class I IHC, 10x. 
Fig. 28. Crl H460 wt; CD31 
IHC, 10x. 
 
Treatment with compound 1 dramatically reduced the number of metastases, whereas results 
obtained with compound 2 were more variable. 
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Comments 
This study allowed to appreciate the metastatic spreading to the lungs of both tested cell lines. This 
finding is in contrast with the results reported by Harris et al. (2011) in which no pulmonary 
spreading was observed with the same cell line implanted subcutaneously in mice at day 49. 
 
The finding of acidophilic macrophage pneumonia (AMP) is an incidental finding, largely described 
by current literature (Murray and Luz, 1990). Any disease process that impairs normal clearance 
such as pulmonary tumors as in this case, or Pneumocystosis or other chronic pneumonias can 
predispose to AMP, that is characterized by the accumulation of acidophilic crystals containing 
iron, alpha-1 antitrypsin, immunoglobulin and breakdown products of granulocytes within 
macrophages and alveolar spaces. 
 
Discriminate between intravascular emboli and metastases was not easy in some samples. In 
general emboli recapitulated the outline of vessels and/or were admixed with erythrocytes. CD31 
immunohistochemistry was performed as an attempt to highlight if clusters of neoplastic cells were 
surrounded by a CD31-positive endothelium (suggestive of an embolus) or not (neoplastic cells 
already extravasated and thus considered as metastases). In this study emboli were added to 
metastases. In the majority of cases the endothelium was discontinuous and thus suggestive of an 
extravasion of neoplastic cells.  
 
The human origin of neoplastic cells was assessed with anti-human MHC class I 
immunohistochemistry. 
 
In conclusion, the described experimental design is a promising model of a pulmonary metastatic 
carcinoma. 
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3.3– Experiment IX- Pulmonary metastases of an intramuscular xenograft sarcoma 
In collaboration with IRCCS, Istituto Nazionale dei Tumori of Milan a promising model of an 
intramuscular sarcoma metastasizing to the lungs was investigated. 
 
The aims of this study were to investigate a promising metastatic sarcoma model and develop an 
immunohistological method able to detect human disseminated tumor cells in murine lungs. 
 
Material and Methods 
Eight SCID mice were injected intramuscularly (IM) or subcutaneously (SC) with 2 or 5 million 
human A204 rhabdomyosarcoma cells and euthanized after 9 weeks. Lungs were formalin-fixed, 
paraffin-embedded, sectioned at 4 µm and stained with Hematoxylin and Eosin (HE) for routine 
histopathological examination. Immunohistochemistry (IHC) and immunofluorescence (IF) were 
performed on serial sections for the assessment of tumor cell dissemination to the lung using 
specific anti-human antibodies, i.e. anti-Vimentin clone sp20 (reported to specifically react with 
human mesenchymal cells) and anti-human MHC class I antibodies. Image analysis was 
performed on Vimentin sp20-stained sections. The number of positive neoplastic cells was counted 
using ImageJ analysis program (http://rsb.info.nih.gov/ij/) in six 400x microscopic fields selected 
within the areas with strongest signal (hot spot fields). Double-immunofluorescence was performed 
to assess if the two markers colocalized. Double immunofluorescently labeled sections were 
acquired with the Leica TCS SPE confocal microscope (Leica Microsystems GmbH, Wetzlar, 
Germany). The fluorophores (Alexa Fluor® 555 Goat Anti-Rabbit IgG (H+L), Molecular Probes® 
and Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L), Molecular Probes®) were excited with the 488 
nm and the 532 nm laser lines and the emitted fluorescence acquired in sequential scan mode with 
ACS APO 10x/0.3 Dry and ACS APO 40x/1.15 Oil CS objectives. Nuclei were visualized by DAPI 
staining (405 nm laser line excitation). 
 
Results 
Detection of neoplastic cells within pulmonary interstitium in HE stained sections was very 
challenging and hampered by the fact that suspected neoplastic cells were closely intermingled 
with murine cells and were not arranged in aggregates recapitulating primary muscular tumor. IHC 
performed on serial sections with anti-Vimentin and anti-human MHC class I antibodies allowed to 
appreciate atypical cells arranged either singly or in small clusters infiltrating pulmonary interstitium 
(Fig. 29 and Fig. 31 and Fig. 30 and Fig. 32, respectively). A blind quantification of the cells 
resulted in a higher number of human neoplastic cells in the lung of mice injected with 5 million 
cells rather than of mice injected with 2 million cells. The mouse injected subcutaneously had the 
lowest numbers of pulmonary metastases, as reported in Table 19. 
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Tab. 19. Results of metastatic evaluation based on Vimsp20 immunohistochemistry. 
Group Sample field a field b field c field d field e field f tot mean 
IM - 2 
million 
A204 
cells 
#1 10 7 12 15 9 9 62 10,3 
#2 14 18 6 3 23 5 69 11,5 
#3 13 3 26 30 8 21 101 16,8 
#4 11 3 9 4 7 6 40 6,7 
tot 
      
272 11,3 
IM- 5 
million 
A204 
cells 
#5 38 56 25 23 30 18 190 31,7 
#6 29 14 10 11 22 6 92 15,3 
#7 10 15 17 17 15 12 86 14,3 
tot 
      
368 20,4 
SC - 5 
million 
A204 
cells 
#8 1 1 4 1 3 4 14 2,3 
 
These results were confirmed by anti-human MHC class I immunohistochemistry and although the 
immunolabeling of this antibody was fainter than that observed with Vimentin sp20, obtained 
results mirrored those achieved with Vimentin alone.  
 
Representative pictures are provided in Figure 29 to 32. 
 
 
Fig. 29. Randomly selected field, sample #1. MHC 
I IHC, 400x. 
Fig. 30. Randomly selected field, sample #1. 
Vimentin IHC, 400x. 
  
  
  
Fig. 31. Randomly selected field, sample #1. MHC 
I IHC, 400x. 
Fig. 32. Randomly selected field, sample #1. 
Vimentin IHC, 400x. 
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To evaluate the specificity of both markers to detect exclusively human tissues, sections from 
either non pathological murine lungs and from lungs with inflammatory lesions were 
immunostained with both Vimentin and anti-human MHC class I. 
 
No specific immunoreactivity was observed, with only a minimal background signal on bronchiolar 
epithelium. Exemplificative pictures are provided in Figures 33 to 35. 
 
 
  
Fig. 33. Focus of histiocytic 
pneumonia, with intralesional 
crystals. HE, 400x. 
Fig. 34. Serial section of Fig. 32. 
No specific immunoreactivity 
observed. Anti-human MHC 
class I IHC, 400x. 
Fig. 35. Serial section of Fig. 32. 
No specific immunoreactivity 
observed. Vimentin sp20 IHC, 
400x. 
 
As a final step, double-immunofluorescence assessed the two markers colocalized in the same 
atypical cells. Exemplificative pictures are provided in Figures 36 to 38. 
   
Fig. 36. Disseminated tumor 
cells infiltrating pulmonary 
interstitium were 
immunofluorescently labelled 
by Vimentin. IF staining, 
confocal, scale bar 50µm. 
Fig. 37. Disseminated tumor 
cells infiltrating pulmonary 
interstitium were 
immunofluorescently labelled 
by MHC I. IF staining, confocal, 
scale bar 50µm. 
Fig. 38. Both markers co-
localized in the same atypical 
cells (yellow) (c and d), thus 
demonstrating that these cells 
were of mesenchymal and 
human origin. Vimentin, MHC I 
and DAPI signal shown. 
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Comments 
This experiment confirmed that rabbit monoclonal anti-Vimentin clone SP20 (Labvision) holds a 
species-specificity for human mesenchymal cells as stated by the Manufacturer’s datasheet, since 
it does not immunolabel FFPE murine tissues. Anti-human MHC class I and Vimentin sp20 are 
useful markers in the detection of human mesenchymal cells and do not cross-react with murine 
tissue. 
 
In conclusion, intramuscular injection of A204 rhabdomyosarcoma cells can be regarded as a 
valuable metastatic orthotopic xenograft model. Immunohistological methods using specific anti-
human antibodies are a reliable tool for the detection of disseminated xenografted tumor cells. 
 
3.4 - Conclusive remarks regarding xenograft metastatic models 
Pulmonary metastases can occasionally be detected grossly with the aid of a stereomicroscope. In 
the majority of cases, a careful histological evaluation is mandatory and allows to detect small 
clusters of neoplastic cells. In other cases, the detection of metastases is even more challenging 
and an immunohistological approach is required to discriminate between human metastatic 
neoplastic cells and interstitial stroma. 
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Conclusions 
Animal models are essential in the study of human malignancies and have a great potential for 
further improvement. In general, the ideal animal model should recapitulate pathogenesis and 
histopathological features, elicit physiological and systemic effects and involve the same genetic 
and biochemical pathways of the human counterpart (Céspedes et al., 2006). In light of these 
considerations, xenografts mouse models are a valuable and promising tool and have been 
extensively used in the study of human malignancies. Nevertheless, there is a lack of 
standardization in current literature, with no detailed guidelines for their sampling and evaluation 
provided so far. 
 
This report aimed at describing a straightforward approach to this model through histopathological 
and immunohistochemical analyses. I would like to stress that these evaluations are 
complementary and not alternative to in vitro analyses and to other evaluations carried on live 
mice, such as the collection of parameters from murine serum, urine, etc. and/or imaging 
techniques. Among these latter, bioluminescence imaging (BLI) has recently emerged as a valid 
method for rapid, cheap, facile screening of tumor growth and spread in mice. BLI can be profitably 
applied to both subcutaneous and orthotopic tumor models with high sensitivity and reproducibility 
and it is used for assessing chemotherapeutic efficacy, drug combinations, dosing and timing 
(Contero et al., 2009).  
 
A combined approach and a strict cooperation between in vivo operators such as biologists and 
technicians and veterinary pathologists both in the set up of experimental protocols and in animal 
monitoring is thus strongly encouraged in order to maximize the amount of data that can be 
collected from sacrificed animals, to optimize the collection of samples and finally to improve the 
quality of scientific data obtained. Furthermore, the veterinary pathologist should be able to provide 
information regarding animal welfare, which is a topic of debate nowadays, raising several ethical 
concerns. 
 
As an attempt to bypass this problem, alternative models eliciting less ethical concerns have 
recently flourished, such as the use of zebrafish. Both adult and juvenile zebrafish (Danio rerio) 
represent in fact a promising alternative model in cancer research (Lam et al., 2006), with peculiar 
emphasis on vascular biology studies. Zebrafish spontaneously develops almost any type of tumor, 
most commonly in testis, gut, thyroid, liver, peripheral nerve, connective tissue and ultimobranchial 
gland and over the past few years, human tumor cell transplantation into zebrafish has developed 
(Lee et al., 2005), later optimized with prevention of rejection obtained by dexamethasone 
administration (Stoletov et al., 2007) or sublethal γ irradiation (White et al., 2008). Despite 
evaluable points of strength such as the possibility to visualize tumor cell, zebrafish model has lots 
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of weak points, first of all the difference in temperature requirement of human vs piscine cells and 
cellular size, with zebrafish vessels and other anatomical structures smaller than the corresponding 
human structures. Overall, although zebrafish are a useful model, there is evidence they won’t 
supplant the use of mammalian model system such as the mouse. 
 
Genetically engineered mouse (GEM) models are an additional strategy allowing to bypass several 
of the weak points depicted for human tumor xenografts. A genetically modified mouse is a mouse 
that has had its genome altered through the use of genetic engineering techniques, so that one or 
more genes thought to be involved in transformation or malignancy are mutated, deleted or 
overexpressed (Richmond and Su, 2008). Briefly, the major advantages with GEM are that these 
mice are immunocompetent, so that tumor microenvironment can mirror the human counterpart 
and that specific genetic abnormalities that are present in human tumors can be reproduced in an 
inducible manner, at specific ages and in the tissue-type or origin (conditional knockout). 
 
Finally, it should be mentioned that pet dogs and cats can be regarded as well as valid model 
tumor systems. The pet population develops spontaneous tumors with histopathologic and biologic 
behavior similar to tumors occurring in humans, thus this underutilized resource that has the 
advantage to lack ethical implications can provide insights into the study of human malignancies 
(MacEwen, 1990; Ranieri et al., 2013). 
 
Overall, all models have strengths and limitations and despite weak points, ethical concerns and 
limitations, animal models will never be completely replaced by in vitro approaches that are poorly 
predictive of the behaviour of the complex system represented by the whole organism. 
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Appendix 1 List of the scientific publications that include the contribution of the approach to 
human xenografts developed in this work. 
 
Mol Cancer Ther. 2013 Oct;12(10):2237-47. 
 
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in 
mice.Rovida A, Castiglioni V, Decio A, Scarlato V, Scanziani E, Giavazzi R, Cesca M. 
 
The development of resistance and progressive disease after treatment with angiogenesis 
inhibitors is becoming a controversial issue. We investigated the experimental conditions that 
cause multireceptor tyrosine kinase inhibitors (RTKI) to augment metastasis and whether 
opportune combinations with chemotherapy could counteract this effect. The renal Renca-luc 
tumor was transplanted orthotopically in the kidney of Balb/c mice, which then were or were not 
nephrectomized. The Lewis Lung carcinoma (LLC) was transplanted in the tibial muscle of C57/Bl6 
mice. Treatment with the RTKI sunitinib started at different stages of tumor progression, mimicking 
neoadjuvant or adjuvant settings. Combination studies with paclitaxel, doxorubicin, cisplatin, 
gemcitabine, and topotecan were done on the LLC model, using opportune regimens. In a 
neoadjuvant setting, sunitinib inhibited Renca-luc tumor growth, prolonging survival despite an 
increase in lung metastasis; treatment after primary tumor surgery (adjuvant setting) or on 
established metastasis prolonged survival and decreased metastasis. Sunitinib increased lung 
metastasis from mice bearing early-stage LLC, but did not affect established metastases (no 
acceleration) from advanced tumors. Combinations with doxorubicin ,topotecan, gemcitabine, but 
not cisplatin and paclitaxel, counteracted the increase in metastasis from LLC, partly reflecting their 
antitumor activity. Histology analysis after sunitinib confirmed tumor vascular changes and 
increased hypoxia. Topotecan at suboptimal daily doses reduced sunitinib-related metastasis, 
reducing tumor hypoxia. Tyrosine kinase inhibitors, as sunitinib, can have adverse malignant 
effects mainly in the neoadjuvant setting. The addition of chemotherapy might influence 
metastasis, depending on each drug mechanism of action and its regimen of administration. 
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J Med Chem. 2012 Dec 13;55(23):10460-74. 
 
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) 
peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. 
Colombo R, Mingozzi M, Belvisi L, Arosio D, Piarulli U, Carenini N, Perego P, Zaffaroni N, De 
Cesare M, Castiglioni V, Scanziani E, Gennari C.  
 
A small library of integrin ligand−paclitaxel conjugates 10−13 was synthesized with the aim of 
using the tumor-homing cyclo[DKP-RGD]peptidomimetics for site-directed delivery of the cytotoxic 
drug. All the paclitaxel−RGD constructs 10−13 inhibited biotinylated vitronectin binding to the 
purified αVβ3 integrin receptor at low nanomolar concentration and showed in vitro cytotoxic 
activity against a panel of human tumor cell lines similar to that of paclitaxel. Among the cell lines, 
the cisplatin-resistant IGROV-1/Pt1 cells expressed high levels of integrin αVβ3, making them 
attractive to be tested in in vivo models. cyclo[DKP-f 3-RGD]-PTX 11 displayed sufficient stability in 
physiological solution and in both human and murine plasma to be a good candidate for in vivo 
testing. In tumor-targeting experiments against theIGROV-1/Pt1 human ovarian carcinoma 
xenotransplanted in nude mice, compound 11 exhibited a superior activity compared with 
paclitaxel, despite the lower (about half) molar dosage used. 
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BioconjugChem. 2012 Aug 15;23(8):1610-22. 
 
Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-
assisted drug delivery. 
Pilkington-Miksa M, Arosio D, Battistini L, Belvisi L, De Matteo M, Vasile F, Burreddu P, Carta P, 
Rassu G, Perego P, Carenini N, Zunino F, De Cesare M, Castiglioni V, Scanziani E, Scolastico C, 
Casiraghi G, Zanardi F, Manzoni L. 
 
The efficacy of taxane-based antitumor therapy is limited by several drawbacks which result in a 
poor therapeutic index. Thus, the development of approaches that favor selective delivery of 
taxane drugs (e.g., paclitaxel, PTX)to the disease area represents a truly challenging goal. On the 
basis of the strategic role of integrins in tumor cell survival and tumor progression, as well as on 
integrin expression in tumors, novel molecular conjugates were prepared where PTX is covalently 
attached to either cyclic AbaRGD (Azabicycloalkane-RGD) or AmproRGD (Aminoproline-RGD) 
integrin recognizing matrices via structurally diverse connections. Receptor-binding assays 
indicated satisfactory-to-excellentαVβ3 binding capabilities for most conjugates, while in vitro 
growth inhibition assays on a panel of human tumor cell lines revealed outstanding cell sensitivity 
values. Among the nine conjugate ensemble, derivative 21, bearing a robust triazole ring 
connected to ethylene glycol units by an amide function and showing excellent cell sensitivity 
properties, was selected for in vivo studies in an ovarian carcinoma model xenografted 
inimmunodeficient mice. Remarkable antitumor activity was attained, superior to that of PTX itself, 
which was associated with a marked induction of aberrant mitoses, consistent with the mechanism 
of action of spindle poisons. Overall, the novel cRGD-PTX conjugates disclosed here represent 
promising candidates for further advancement in the domain of targeted antitumor therapy. 
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Br J Cancer. 2012 Jul 10;107(2):360-9. 
 
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, 
and survival of ovarian carcinoma xenograft models. 
Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, Scanziani E, Belotti D, Giavazzi R.  
 
BACKGROUND: Bevacizumab is being incorporated as first-line therapy with standard-of-care 
chemotherapy on epithelial ovariancarcinoma (EOC). We investigated bevacizumab combined with 
chemotherapy on tumour progression and mouse survival in EOC xenograft models. 
METHODS: Bevacizumab was administered concomitantly with cisplatin plus paclitaxel 
(DDPþPTX), continued after induction(maintenance) or started after chemotherapy. The effect on 
tumour progression was monitored by bioluminescence imaging (BLI)(1A9-luc xenograft). Tumour 
dissemination into the peritoneal organs and ascites formation (HOC22 xenograft) was evaluated 
byhistological analysis at the end of treatment (interim) and at euthanasia (survival). The effects on 
overall survival (OS) were nvestigated in both EOC models. 
RESULTS: Bevacizumab with PTXþDDP delayed tumour progression in mice bearing EOC 
xenografts. OS was significantly extended, with complete responses, by bevacizumab continued 
after stopping chemotherapy in the HOC22 xenograft. Bevacizumab alone inhibited ascites 
formation, with only limited effect on tumour burden, but combined with PTXþDDP reduced ascites 
and metastases. Bevacizumab started after induction with PTXþDDP and maintained was equally 
effective on tumour progression and survival on 1A9-luc xenograft. 
CONCLUSION: Bevacizumab combined with chemotherapy not only affected tumour progression, 
but when administered as maintenance regimen significantly prolonged survival, reducing ascites, 
and tumour dissemination. We believe our findings are consistent with the clinical results and shed 
light on the potential effects of this kind of treatment on tumour progression. 
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J Clin Endocrinol Metab. 2013. [in press]. 
 
Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human 
medullary thyroid cancer.  
Lopergolo A, Nicolini V, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani S, BorrelloMG, 
Zaffaroni N, Cassinelli G, Lanzi C.  
 
PURPOSE: Tyrosine kinase (TK) inhibitors represent a new option for patients with advanced 
medullary thyroid cancer (MTC). However, cures have not been achieved with current available 
agents used in monotherapy. Since cisplatin can activate CD95 death receptor, we investigated 
the potential of the TK inhibitor sunitinib in combination with cisplatin to enhance apoptosis 
activation through the extrinsic pathway in Ret TK-dependent MTC preclinical models by exploiting 
the interplay of Ret with CD95-mediated pathway. 
EXPERIMENTAL DESIGN: The effects of sunitinib and cisplatin, alone and in combination, were 
examined in human MTC cell lines harboring oncogenic RET mutations. In vitro and in vivo 
experiments were designed to explore drug activity on Ret signaling, cell growth, apoptosis, 
autophagy, tumor growth, and to investigate the mechanisms of the drug interaction. 
RESULTS: Sunitinib and cisplatin synergistically inhibited the growth of MZ-CRC-1 cells harboring 
the RET M918T activating mutation. The two drugs in combination enhanced caspase activation 
through CD95-mediated apoptosis pathway. Sunitinib induced a perturbation of the autophagic flux 
characterized by autophagosome accumulation and a remarkable lysosomal dysfunction which 
was further enhanced, with likely leakage, by cisplatin. Administration of the two drugs in 
combination improved the antitumor efficacy against MZ-CRC-1 xenografts and increased 
apoptosis in tumor cells as compared to single agent treatments. 
CONCLUSION: Preclinical evidence of a synergistic drug cooperation suggests that addition of 
cisplatin to sunitinib may be promising in a clinical combination treatment regimen for advanced 
sporadic or hereditary MTCs harboring the RET M918T oncogene. 
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ESVP/ECVP Meeting, London (UK), September 4th-7th 2013, poster presentation. 
 
Immunohistological identification of disseminated tumor cells in the lungs of a mouse orthotopic 
xenograft model of human rhabdomyosarcoma.  
Castiglioni V, De Maglie M, Rodighiero S, Cassinelli G, Lanzi C, Scanziani E, Recordati C.  
 
INTRODUCTION: Murine xenografts are extensively used in the study of human malignancies. 
One of the major criticism of this animal model is its low metastatic potential. The aims of this study 
were to investigate a promising metastatic sarcoma model and to validate an immunohistological 
method able to detect human disseminated tumor cells in murine lungs. 
MATERIALS AND METHODS: 7 SCID mice were injected intramuscularly with human A204 
rhabdomyosarcoma cells and euthanized after 9 weeks. Standard histology, immunohistochemistry 
and immunofluorescence using specific anti-human Vimentin and MHCI antibodies were used for 
the assessment of tumor cell dissemination to the lungs.  
RESULTS: Histological examination alone was not successful in identifying neoplastic 
dissemination to the lungs. Immunohistochemical methods enhanced the sensitivity of the analysis 
and both Vimentin and MHCI allowed to appreciate either single or clustered cells of human origin 
within pulmonary interstitium. Both markers co-localized in the same atypical cells with double-
immunofluorescence. 
CONCLUSION: Intramuscolar injection of A204 rhabdomyosarcoma cells can be regarded as a 
valuable metastatic orthotopic xenograft model. Double immunofluorescence using specific anti-
human Vimentin and MHC I is a promising tool in the detection of pulmonary disseminated tumor 
cells. 
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Appendix 2: List of the scientific publications that do not involve human tumor xenografts. 
 
J Toxicol Pathol [in press] 
 
Immunohistochemical characterization of a renal nephroblastoma in a Trp53-mutant and prolyl 
isomerase 1-deficient mouse. 
Castiglioni V, De Maglie M, Queliti R, Rustighi A, Del Sal G, and Radaelli E. 
 
A nephroblastoma is a tumor arising from metanephric blastema occurring in childhood. Among 
laboratory rodents, nephroblastoma has been frequently reported in rats, but it remains 
exceedingly rare in mice. The present work describes a nephroblastoma in a young mouse 
homozygous for the specific Trp53 R172H point mutation coupled with targeted deletion of the 
Pin1 gene. The affected kidney was effaced by a biphasic tumor with an epithelial component 
arranged in tubules surrounded by nests of blastemal cells. Immunohistochemically, the neoplasm 
was diffusely positive for Wilms’ tumor antigen. The epithelial component expressed markers 
ofrenal tubular differentiation including wide-spectrum cytokeratin, E-cadherin and folate-binding 
protein. Furthermore, the neoplasm exhibited a high proliferative index and diffuse 
nucleocytoplasmic β-catenin expression. Based on histological and immunohistochemical features, 
a diagnosis of nephroblastoma potentially associated with Trp53 loss and oncogenic β-catenin 
activation has been proposed. 
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Vet Microbiol. 2012 Sep 14;159(1-2):107-14. 
 
Enterohepatic Helicobacter spp. in colonic biopsies of dogs: molecular, histopathological and 
immunohistochemical investigations. 
Castiglioni V, Vailati Facchini R, Mattiello S, Luini M, Gualdi V, Scanziani E, Recordati C.  
 
Enterohepatic Helicobacter spp. have been described colonizing the large intestine and liver of 
healthy and symptomatic subjects and are thought to have a role in the development of 
inflammatory bowel disease (IBD). The prevalence of enterohepatic Helicobacter spp. infection in 
dogs is largely unknown and to our knowledge there are no data about their potential pathogenic 
role. In light of these considerations, the aims of this study were (i) to assess the prevalence of 
enterohepatic Helicobacter spp. in colonic biopsies of symptomatic pet dogs and (ii) to evaluate a 
possible association between Helicobacter spp. colonization status (heavily colonized, poorly 
colonized and uncolonized biopsies) and histological lesions. Colonic biopsies from 27 pet dogs of 
different ages were evaluated by family Helicobacteraceae and enterohepatic Helicobacter spp. 
PCR, histology,and immunohistochemistry for the in situ detection of Helicobacter spp. organisms. 
85%and 52% of colonic biopsies were positive by Helicobacteraceae and enterohepatic 
Helicobacter spp. PCR, respectively. Immunohistochemistry revealed Helicobacter spp. were 
localized both in the superficial mucus (55%) and within intestinal crypts (33%). Dogs with heavy 
enterohepatic Helicobacter spp. colonization were significantly younger and had a higher level of 
mucosal fibrosis/atrophy than dogs with uncolonized or poorly colonized biopsies (p < 0.05). These 
findings contribute to widen current knowledge regarding canine enterohepatic Helicobacter spp., 
suggesting the infection is rather common in dogs and acquired at an early age. Furthermore, 
heavy colonization of colonic crypts is associated with chronic inflammatory lesions 
(fibrosis/atrophy), supporting the role of enterohepatic Helicobacter spp. in the development of 
canine IBD. 
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Vet Rec. 2012 Mar 24;170(12):312. 
 
Long-term study of MRSA ST1, t127 mastitis in a dairy cow. 
Pilla R, Castiglioni V, Gelain ME, Scanziani E, Lorenzi V, Anjum M, Piccinini R.  
 
METICILLIN-resistant Staphylococcus aureus (MRSA) has been reported in human medicine as a 
cause of nosocomial and community-associated infections (Otter and French 2010). In veterinary 
medicine, MRSA strains have been identified in a wide range of animals and diseases(Leonard 
and Markey 2008, Fessler and others 2009, Huber and others2010, Turkyilmaz and others 2010), 
thus it is considered an emerging threat with a high zoonotic potential (Juhasz-Kaszanyitzky and 
others2007). MRSA sequence type (ST) 1, spa type (t) 127 has been mostly isolated from 
community-associated infections, but t127 has seldom been identified in cattle and pigs (Hasman 
and others 2010).The present report regards a dairy cow with an intramammary infection by MRSA 
ST1, t127 that was investigated over an entire lactation and submitted to histological evaluation of 
mammary tissue to explore both bacterial molecular features and host immune response in the 
milk and mammary tissue. The study was performed because only a few mammary infections of 
the dairy cow by this particular strain have been reported and no information is available on the 
interaction between the bacteria and the mammary gland. 
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Res Vet Sci. 2011 Oct;91(2):251-3.  
 
Outbreak of bovine clinical mastitis caused by Mycoplasma bovis in a North Italian herd. 
Radaelli E, Castiglioni V, Losa M, Benedetti V, Piccinini R, Nicholas RA, Scanziani E, Luini M.  
 
This report describes an outbreak of Mycoplasma bovis mastitis affecting 45 cows in a herd of 122 
dairy cattle in Northern Italy. Clinically, the outbreak was characterized by agalactia, multiple 
swollen and painless quarters, high milk somatic cell count and unresponsiveness to conventional 
antibiotic therapy.M. bovis was isolated from the milk samples of all the 32 affected cows tested 
and from the mammary tissue of three affected cows that underwent necropsy. No other 
pathogens were isolated from these samples. Lesions in two of the necropsied cows were 
characterized by mild chronic suppurative mastitis and galactophoritis. The other necropsied cow 
showed a chronic necrosuppurative and pyogranulamaous galactophoritis, a condition not 
previously associated with M. bovis. M. bovis was detected immunohistochemically in the lumen of 
the affected mammary ducts suggesting that ascending infection via the teat canal was the likely 
route of transmission. No other intralesional pathogens were demonstrated microscopically. 
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Histol Histopathol. 2011 Mar;26(3):285-96. 
 
Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-
vascular endothelial growth factor transgenic mice. 
Canavese M, Altruda F, Silengo L, Castiglioni V, Scanziani E, Radaelli E.  
 
Up-regulation of vascular endothelial growth factor (VEGF) plays a primary role in the 
pathogenesis of psoriasis. Transgenic mice over-expressing VEGF under the Keratin 14 (K14) 
promoter develop an inflammatory skin condition with many of the pathobiological features of 
human psoriasis. In this work, the development of spontaneous psoriatic-like dermatitis in K14-
VEGF transgenic mice was monitored from week 6 to week 44 and skin lesions were characterized 
clinically (application of a clinical score system comparable to the human Psoriasis Area and 
Severity Index), microscopically (histopathology, leukocyte subset and neoangiogensis) and 
immunologically (evaluation of local and systemiccytokine/chemokine profiles).Based on PASI 
score system, three progressive clinical phases were identified: mild acute (8-14 weeks of age), 
moderate subacute (15-21 weeks of age) and severe chronic-active (22-44 weeks of age) 
dermatitis. Microscopically, skin lesions consisted of progressive proliferative psoriatic-like 
dermatitis dominated by dermo-epidermal infiltrates of CD3-positivelymphocytes, an increased 
number of mast cells and neoangiogenesis. Both local and systemic up-regulation of pro-
inflammatory (IL-12, TNF-alpha, IL-6, MCP-1and IL-8) and regulatory (IL-10) cytokines/chemokines 
was observed, mainly during the later stages of disease development. The results obtained in this 
study further confirm the central role of VEGF over-expression in the development of psoriatic-like 
dermatitis. Similarly to what is reported for human psoriasis, both the local and systemic 
immunologic profiles observed in K14-VEGFtransgenic mice suggest that a combined Th1 and 
Th17response may be implicated in lesion development. The identification of three progressive 
stages of disease, each with peculiar clinicopathological features, renders theK14-VEGF 
transgenic mouse a valuable model to study novel immunotherapies for psoriasis. 
